- Home
- ARVN vs IMKTA Comparison
ARVN vs IMKTA Comparison
Compare ARVN & IMKTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- IMKTA
- Stock Information
- Founded
- ARVN 2015
- IMKTA 1963
- Country
- ARVN United States
- IMKTA United States
- Employees
- ARVN N/A
- IMKTA N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- IMKTA Food Chains
- Sector
- ARVN Health Care
- IMKTA Consumer Staples
- Exchange
- ARVN Nasdaq
- IMKTA Nasdaq
- Market Cap
- ARVN 1.4B
- IMKTA 1.2B
- IPO Year
- ARVN 2018
- IMKTA N/A
- Fundamental
- Price
- ARVN $18.57
- IMKTA $64.43
- Analyst Decision
- ARVN Strong Buy
- IMKTA
- Analyst Count
- ARVN 13
- IMKTA 0
- Target Price
- ARVN $63.00
- IMKTA N/A
- AVG Volume (30 Days)
- ARVN 860.7K
- IMKTA 139.0K
- Earning Date
- ARVN 02-25-2025
- IMKTA 02-06-2025
- Dividend Yield
- ARVN N/A
- IMKTA 1.02%
- EPS Growth
- ARVN N/A
- IMKTA N/A
- EPS
- ARVN N/A
- IMKTA 5.56
- Revenue
- ARVN $161,100,000.00
- IMKTA $5,639,609,434.00
- Revenue This Year
- ARVN $239.85
- IMKTA N/A
- Revenue Next Year
- ARVN N/A
- IMKTA N/A
- P/E Ratio
- ARVN N/A
- IMKTA $11.35
- Revenue Growth
- ARVN 1.07
- IMKTA N/A
- 52 Week Low
- ARVN $17.08
- IMKTA $59.73
- 52 Week High
- ARVN $53.08
- IMKTA $85.87
- Technical
- Relative Strength Index (RSI)
- ARVN 43.53
- IMKTA 45.33
- Support Level
- ARVN $17.35
- IMKTA $63.01
- Resistance Level
- ARVN $21.00
- IMKTA $64.77
- Average True Range (ATR)
- ARVN 1.18
- IMKTA 1.56
- MACD
- ARVN 0.12
- IMKTA 0.18
- Stochastic Oscillator
- ARVN 38.01
- IMKTA 69.21
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About IMKTA Ingles Markets Incorporated
Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.